Abstract: A user equipment (UE) controls power consumption of the UE based on mobility information and channel conditions experienced by the UE. In one instance, the UE determines its level of mobility based on a Doppler frequency spread of received communications. The UE disables a motion sensor when the level of mobility is above a first threshold. The UE then controls the communications based on the motion sensor and channel conditions experienced by the UE when the level of mobility is below the first threshold.

Abstract: The present invention is directed to crystalline addition salts of (ii) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present disclosure relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I), and to their methods of use in therapy.

Abstract: The present invention is directed to a pharmaceutically acceptable crystalline addition salt of 5-[(1R)-2-({2-[4-({4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one, and (ii) a dicarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvate thereof.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present disclosure relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present disclosure relates to a mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the ?2 receptor.

Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.

Abstract: Advanced Motion Detection in Wireless Communication Systems processes accelerometer or other sensor input data to distinguish between random in-place movements and actual start of motion that could produce a change in the user's location by filtering unsustained random motion. Random in-place motion such as table banging, knee jiggling, vibration, etc. are filtered out from Stationary and Non-Stationary motion state determinations. The process utilizes data from motion sensors or any accelerometer standard in all smart mobile devices and any mobile device that has automatic portrait-landscape switching (screen rotation). A state machine processes sensor or other input to produce a filtered Stationary or Non-Stationary output movement state unaffected by transient motion or rest periods.

Abstract: Motion status states reported by an advanced motion detection process or other means of obtaining a movement state of Stationary or Non-Stationary from filtered accelerometer data are utilized to reacquire service during Out of Service scenarios. Both movement states operate in three power phases: aggressive scanning or normal power mode, slow scanning or moderate power mode, and deep sleep or power saving mode. The scanning rate, power mode, scanning period and/or channel list depend upon the movement state and power phase. Motion information obtained from an advanced motion detection process provides substantial improvements in service reacquisition performance and power consumption in stationary Out of Service scenarios. When compared to traditional service reacquisition scanning routines, the reductions in average current can be achieved of: at a 5-minute OOS mark, ˜45% reduction, at a 15-minute OOS mark, ˜60% reduction and at a 6-hour OOS mark, ˜50% reduction.

Abstract: The present disclosure relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present disclosure relates to crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and pharmaceutically acceptable solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and to methods of treatment comprising these pharmaceutical compositions.